VANCOUVER, British Columbia, July 30, 2026 – Frequency Exchange Corp. (TSXV: FREQ) (OTC: FRECF) ("Frequency”) announces that its wholly owned operating subsidiary, FREmedica Technologies Inc. (“FREmedica” or the “Company”), announces the commercial launch of its NIKKI Lyme Wellness Program through Ergopathics.
Under the commercial referral relationship, Ergopathics will make the NIKKI Lyme Wellness Program available to practitioners who use Ergopathics' frequency-based assessment technology. Clinics determine independently whether to recommend or offer NIKKI to patients. The arrangement does not include minimum purchase commitments, guaranteed clinic participation, or guaranteed sales. Ergopathics conducted a survey of their clients and received a very positive indication that they will incorporate NIKKI into their practices.
Ergopathics currently serves a network of more than 7,000 practitioner clinics in the United States. The launch provides FREmedica with the opportunity to introduce NIKKI to practitioners within that network. Access to the network does not mean all clinics have agreed to carry or recommend NIKKI. These clinics already use frequency-based wellness programs used to identify the health issue and NIKKI delivers the same frequency-based wellness programs to support the healing process.
“This launch represents an important commercial milestone for NIKKI,” said Stephen Davis of Frequency Exchange Corp. “The Ergopathics relationship with NIKKI gives them the missing piece to their diagnostic technology they currently provide to their clinic base. This is the first of many partnerships where NIKKI closes the loop between tracking and overcoming the health issues you track.”
The initial rollout will focus on the NIKKI Lyme Wellness Program. Subject to market acceptance and the ongoing commercial referral relationship, the companies may evaluate introducing additional NIKKI wellness programs supporting sleep, stress, energy, and recovery. Sleep and stress affects everyone at some point in their life and affects our life on many levels.
Ergopathics has built its reputation over the last 20 years by providing practitioners with frequency-based assessment technology that helps identify health and wellness concerns. Through this commercial referral relationship, practitioners who choose to do so may also offer NIKKI as a complementary wellness solution following those assessments. NIKKI creates a closed loop wellness program as the practitioner is now able to support what they track using the same frequency-based technologies. These two approaches to health support each other giving the patient a very good outcome.
About FREmedica Technologies Ltd.
FREmedica Technologies Ltd. is a health technology company developing proprietary frequency-based wellness solutions. Its flagship wearable, NIKKI, delivers non-invasive wellness programs designed to support the body’s natural ability to restore balance.
About Ergopathics
For more than 20 years, Ergopathics has provided frequency-based assessment tools to wellness practitioners worldwide, helping them identify areas of concern and offer personalized wellness recommendations. Learn more at: www.ergopathics.com
About Frequency Exchange Corp.
Frequency Exchange Corp. is the parent company of FREmedica Technologies Inc., a technology company focused on frequency-based digital wellness solutions designed to support cellular communication and broader wellness applications.
Originally developed with applications related to Lyme disease, the NIKKI platform has evolved into a wellness solution addressing sleep, stress, recovery, and performance — areas of increasing demand in international markets, including the Middle East. The Company’s technology is supported by ongoing testing and quality-of-life evaluations.
More information is available at:
Investor Contacts
Frequency Exchange Corp.
Stephen Davis
CEO
Stephen@frequencyexchangecorp.com
604-684-2181
FREmedica Technologies Inc.
Nicole Sullivan
President
Nicole.sullivan@wearenikki.com
604-684-2181
Forward-Looking Information
This news release includes certain forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation including the proposed Private Placement and use of proceeds. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Forward-looking information in this news release includes statements concerning the Company's general business plans. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors that could materially affect such forward-looking information are described in the risk factors in the Final Prospectus, and the schedules attached thereto, that are available on the Company's profile on SEDAR+ at www.sedarplus.ca.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.